Slope of Hope Blog Posts

Slope initially began as a blog, so this is where most of the website’s content resides. Here we have tens of thousands of posts dating back over a decade. These are listed in reverse chronological order. Click on any category icon below to see posts tagged with that particular subject, or click on a word in the category cloud on the right side of the screen for more specific choices.


By -

As we wrap up quadruple-witching week, let’s take a fresh look at five important cash indexes.

We begin with the Dow Composite (also known as the Dow 65). It’s all about that tinted line, folks. Cross above it, and the bulls are going to take this decade-long bull market to new highs. Continue to be repelled by it, and the countertrend rally that start on Christmas is going to crumble.


The Ides of OPEX (by Moneymiser21)

By -

Ah mid-March. College basketball conference tournaments, and NCAA tourney dreams. (Note from Tim: I guess I didn’t really have to identify the author as someone besides myself. Anyway.)

And of course some high probability seasonality trade opportunities, both bearish and bullish as March monthly options expiration comes to an end.

One year ago, Slope nailed the Facebook and Google plunges before they happened (And boy did that FB plunge happen!).

And based on Thursday’s price action, the bears appear to be warming up the bandwagon once again.


Running on Earnings

By -

Here are four stocks to watch with strong price momentum fueled by earnings.  

Denali Therapeutics Inc. (DNLI) jumped $2.17 to $24.37 on 1.19 million shares Wednesday, nearly 3 times its average volume. The move followed Tuesday’s earnings release by the biopharmaceutical company, which is developing treatments for neurodegenerative diseases.  With the move, the stock took out multiple tops, and looks like it could extend further.  Watch next for a test of the February high near $25.75.

Guardant Health, Inc. (GH) exploded for $24.45, or 27.6%, to $94.45 on 3.7 million shares Wednesday, 3 1/2 times its average volume.  The move came as the cancer diagnostics company beat Wall Street expectations in its fourth quarter earnings report.  The stock is extended and could pull back and consolidate, but eventually ride the rising channel up to above $120.